Impact of Adherence to Anemia Management Policy on Repeat Hospitalization in End Stage Renal Disease (ESRD)

April 1, 2010 updated by: Fresenius Medical Care North America

A Case Controlled Study to Determine the Impact of Adherence to Anemia Management Policy on Repeat Hospitalization in ESRD

The investigators hypothesize that the post-hospitalized patient status is characterized by subacute and reversible metabolic and hematological changes that, if addressed and treated in a timely manner, would result in a reduced risk for repeat hospitalization. Consequently, a structured quality improvement program, focused on increasing adherence to company wide anemia management policies (ie hemoglobin monitoring within the first 3-5 days post-hospitalization, followed by an appropriate EPO dose modification within the 7 days post-hospitalization), will significantly decrease the risk of hospital re-admission in the 30 days after discharge.

Study Overview

Detailed Description

The post-hospitalization quality improvement project will be piloted across 30 Fresenius clinics. Targeted enrollment of 1500 episodes of hospitalization in which the patient returns after discharge to resume outpatient dialysis.

Patient outcomes will be followed for up to 30 days from the time of discharge from hospital.

Study Type

Interventional

Enrollment (Anticipated)

1500

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Colorado
      • Denver, Colorado, United States, 80209
        • Denver Central
    • Florida
      • Jacksonville, Florida, United States, 32246
        • St. John's
      • Jacksonville, Florida, United States, 32250
        • JAX Beach
    • Illinois
      • Chicago, Illinois, United States, 60616
        • Prairie
    • Indiana
      • Decatur, Indiana, United States, 46733
        • Tri Counties
      • Huntington, Indiana, United States, 46750
        • Huntington
      • New Albany, Indiana, United States, 47150
        • Floyd County
    • Kentucky
      • Louisville, Kentucky, United States, 40216
        • South Louisville
    • Louisiana
      • Breaux Bridge, Louisiana, United States, 70517
        • Breaux Bridge
      • Delta, Louisiana, United States, 71233
        • Delta
      • Lafayette, Louisiana, United States, 70501
        • East Lafayette
    • Massachusetts
      • Methuen, Massachusetts, United States, 01844
        • Methuen
      • Roxbury, Massachusetts, United States, 02119
        • Roxbury
    • Michigan
      • Battle Creek, Michigan, United States, 49014
        • Battle Creek
      • East Lansing, Michigan, United States, 48823
        • East Lansing
      • Kalamazoo, Michigan, United States, 49009
        • Oshtemo
      • Lansing, Michigan, United States, 48911
        • Lansing
      • Saginaw, Michigan, United States, 48602
        • Saganaw Riverside
      • Saginaw, Michigan, United States, 48602
        • Saginaw
    • Mississippi
      • Eupora, Mississippi, United States, 39744
        • Eupora
      • Meridian, Mississippi, United States, 39301
        • Meridian
      • Oxford, Mississippi, United States, 38655
        • Yokna River
    • Missouri
      • Independence, Missouri, United States, 64057
        • Independence Centerpoint
    • Nevada
      • Las Vegas, Nevada, United States, 89109
        • Desert Inn
      • Las Vegas, Nevada, United States, 89120
        • South Pecos
    • North Carolina
      • Durham, North Carolina, United States, 27703
        • Briggs Ave
      • Durham, North Carolina, United States, 27704
        • Freedom Lake
    • Ohio
      • Boardman, Ohio, United States, 44512
        • Boardman
      • Cortland, Ohio, United States, 44410
        • Cortland
      • Elyria, Ohio, United States, 44035
        • Elyria
      • North Randall, Ohio, United States, 44128
        • North Randall
      • Westlake, Ohio, United States, 44145
        • Westlake
      • Willoughby, Ohio, United States, 44094
        • Willoughby
    • Oregon
      • Beaverton, Oregon, United States, 97006
        • Twin Oaks
      • Clackamas, Oregon, United States, 97015
        • Clackamas
    • Tennessee
      • Brentwood, Tennessee, United States, 37027
        • Fresenius Medical Services
      • Smyrna, Tennessee, United States, 37167
        • Smyrna
      • West Nashville, Tennessee, United States, 37209
        • West Nashville
    • Texas
      • Fort Worth, Texas, United States, 76119
        • North Fort Worth
      • Fort Worth, Texas, United States, 76119
        • Tarrant County
      • Waco, Texas, United States, 76708
        • Waco
      • Waco, Texas, United States, 76712
        • Waco West

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • age ≥ 18
  • resumption of routine outpatient chronic hemodialysis within three days of discharge from hospital admission
  • enrolled in a facility-based anemia management program

Exclusion Criteria:

  • enrolled in hospice
  • previous hospitalization within the past 30 days (ie. patients discharged from a repeat hospitalization)
  • anticipated discharge from the outpatient dialysis facility within 30 days (ie anticipated transfer to another facility or hospice)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Early anemia management
Upon return to the dialysis unit following hospitalization, patients will be immediately identified and have immediate implementation of the unit anemia protocol rather than waiting for the next regularly scheduled unit labs and regular follow-up. Thus, labs will be obtained within the first 3-7 days following hospitalization and appropriate titration of Epo and iron medications within the 7 days after discharge from hospital and under the direction of the pre-specified algorithm used in the patient's facility; all drug dosing will comply with package insert instructions
Patients returning to the unit are immediately assessed and treated for anemia
Other: case control
Each case will be "data-matched" to an intra-facility (primary control), and then an inter-facility (validation control) control patient. Matching criteria will be by age, gender, diabetic status, attending nephrologist, length of hospitalization stay, and hospital discharge date (to minimize the difference in the date between the case and control). These patients did not have early intervention but followed the usual practice of waiting for the next regularly scheduled dialysis unit labs with anemia management to follow using the regular unit algorithm.
Normal unit policy for labs and anemia treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
composite of death or repeat hospitalization within the 30 days after discharge from a previous hospitalization
Time Frame: one year to accumulate 1500 hospitalizations
one year to accumulate 1500 hospitalizations

Secondary Outcome Measures

Outcome Measure
Time Frame
hemoglobin, transferrin saturation, albumin, white blood cell count, and C-reactive protein* levels measured in the period following hospitalization and change relative to values measured prior to hospitalization (where available).
Time Frame: one year to accumulate 1500 hospitalizations
one year to accumulate 1500 hospitalizations

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Raymond Hakim, M.D., Ph.D., Fresenius Medical Services

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2009

Primary Completion (Anticipated)

November 1, 2010

Study Completion (Anticipated)

December 1, 2010

Study Registration Dates

First Submitted

November 18, 2009

First Submitted That Met QC Criteria

November 19, 2009

First Posted (Estimate)

November 20, 2009

Study Record Updates

Last Update Posted (Estimate)

April 2, 2010

Last Update Submitted That Met QC Criteria

April 1, 2010

Last Verified

April 1, 2010

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 20090068

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mortality

Clinical Trials on Early anemia diagnosis and treatment

3
Subscribe